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ABSTRACT 6 
Objectives: To assess the clinical feasibility of whole body diffusion-weighted magnetic 7 
resonance imaging (WB-DWI/MRI) for diagnosis and prediction of complete tumour 8 
resection in patients with suspected recurrent ovarian cancer. 9 
Methods: Fifty-one women clinically suspected for ovarian cancer recurrence underwent 10 
3-Tesla WB-DWI/MRI in addition to contrast-enhanced computed tomography (CT). 11 
WB-DWI/MRI was assessed for detection of tumour recurrence, -prediction of tumour 12 
extent and complete resection compared to CT. Tumour presence was confirmed by 13 
pathology obtained by surgery or biopsy, or by imaging follow-up. 14 
Results: WB-DWI/MRI showed 94% accuracy for detecting ovarian cancer recurrence, 15 
compared to78% for CT (p=0.008). WB-DWI/MRI showed better sensitivity (Sens (%) 16 
[95% CI]) than CT for detecting involvement of surgically-critical tumour sites including 17 
mesenteric root infiltration (92 [62-100] versus 31 [10-61]), small bowel (93 [64-100] 18 
versus 21 [6-51]),colon carcinomatosis (91 [57-100] versus 27 [7-61]) and irresectable 19 
distant metastases (90 [54-99] versus 20 [4-56]). WB-DWI/MRI correctly predicted 20 
complete resection in 33 of 35 (94%) patients eligible for salvage surgery compared 17 21 
of 35 (49%) for CT (p<0.001). 22 
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Conclusions: WB-DWI/MRI allowed better detection of ovarian cancer recurrence and 23 
better prediction of complete resection compared to CT. 24 
Advances in knowledge: WB-DWI/MRI could assist in optimizing treatment planning 25 
for recurrent ovarian cancer, particularly by improving patient selection for salvage 26 
surgery, thus giving eligible patients the highest chance on prolonged survival and 27 
refraining patients who would not benefit from extensive surgery reducing related 28 
morbidity and mortality. 29 
  30 
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INTRODUCTION 31 
Despite continuing improvement of treatment of ovarian cancer patients, up to 85% of 32 
these women will develop tumour recurrence.1-4 While debulking surgery is well accepted 33 
for treatment of primary ovarian cancer, the surgical management of recurrent disease 34 
remains controversial due to lack of major supporting prospective data and lack of well-35 
defined operability criteria that may predict complete resection. A recent multicentre trial 36 
(DESKTOP II) prospectively developed the ‘Arbeitsgemeinschaft Gynaekologische 37 
Onkologie’ (AGO-) score providing a clinical tool to select patients for salvage surgery.5 38 
Complete resection at primary surgery, good performance status and absence of ascites 39 
represented a likelihood of 76% for secondary debulking to no residual tumour.5 40 
However, eligibility for salvage surgery largely depends on accurate and timely detection 41 
of tumour recurrence and accurate description of total tumour extent. The role of 42 
computed tomography (CT) and 18-fluoro-2-deoxy-D-glucose positron emission 43 
tomography (FDG-PET)/CT for the detection of recurrent ovarian cancer has been 44 
established. However, their value for predicting complete resection remains controversial, 45 
because commonly disease load is underestimated.5-7 Diffusion-weighted MRI (DWI) 46 
distinguishes itself from conventional MRI sequences by the ability to detect water 47 
molecule displacements at a cellular scale (in the order of 10–30 μm) allowing functional 48 
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characterization of tissue microstructural properties. The signal intensity of lesions 49 
depends on the amount of impediment of the movement of water molecules. The more 50 
water molecule movement is restricted in tissues (e.g. tumoral lesions), the brighter 51 
lesions appear at heavily diffusion-weighted images (b = 1000 s/mm²), in contrast to the 52 
suppressed background tissue, ascites and blood vessels.8 The combination of this high 53 
contrast-ratio, spatial resolution in the order of millimetres, robust performance, and short 54 
imaging times allows DWI to depict small tumour deposits in large body volumes in a 55 
clinically time-efficient way. For primary ovarian cancer, studies with abdominal and 56 
whole body diffusion-weighted MRI (WB-DWI/MRI) have indicated high sensitivity for 57 
detecting metastases allowing to predict incomplete resection.9-11 The purpose of this 58 
study was to assess the clinical feasibility of WB-DWI/MRI for diagnosis of patients with 59 
suspected recurrent ovarian cancer and prediction of complete tumour resection. 60 
 61 
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METHODS AND MATERIALS 63 
Patients 64 
Between July 2011 and June 2013, patients clinically suspected for recurrent ovarian 65 
cancer were prospectively and consecutively enrolled. The local ethics committee 66 
approved this study and all patients provided written informed consent. Inclusion criteria 67 
were (1) suspicion of recurrent ovarian cancer based on clinical symptoms (eg. bloating, 68 
pelvic or abdominal pain, diarrhoea or constipation), clinical examination (including 69 
gynaecological ultrasound) and/or increase of cancer antigen (CA)-125 and (2) Complete 70 
resection and completion of all chemotherapy cycles during primary treatment. Patients 71 
with contra-indications to MRI (eg. pacemaker, claustrophobia, MRI incompatible 72 
devices or implants) were excluded. All patients underwent WB-DWI/MRI in addition to 73 
the clinical CT scan and imaging data were read blinded to other imaging and 74 
clinical/biochemical results.  75 
At the oncologic board, patients were first decided on their clinical eligibility for salvage 76 
surgery based on the presence or absence of medical comorbidities, complicated primary 77 
surgery with abscesses or fistulisation preventing major surgery and the DESKTOP II 78 
criteria including Primary R0 resection, good performance status, absence of ascites.12 In 79 
these patients, operability was then decided on the imaging appearance of disease spread 80 
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according to institutional surgical criteria, with disease spread compromising surgery 81 
consisting of distant irresectable metastases, carcinomatosis of the duodenum, stomach, 82 
pancreas, large vessels of the coeliac trunk and hepatoduodenal ligament, metastases 83 
behind the portal vein, diffuse serosal small bowel or colon carcinomatosis or deep 84 
tumoral involvement of the superior mesenteric artery and mesenteric root.12  85 
In case of conflicting WB-DWI/MRI and CT findings for recurrence detection or 86 
operability assessment potentially compromising curative treatment correlative invasive 87 
or imaging diagnostic tests were performed prior to treatment decision (Figure 1). 88 
 89 
CT scanning 90 
Breath-hold contrast-enhanced CT (Sensation 16, Sensation 64, Definition Flash, 91 
Siemens Medical Systems, Erlangen, Germany) was obtained, 90 minutes after per-oral 92 
contrast ingestion [30 ml iodinated contrast agent (Telebrix Gastro, Guerbet), 300 mg/ml, 93 
in 900 ml water], chest scan 17 s and abdomen scan 90 s after intravenous contrast 94 
injection [120 ml iodinated contrast agent (Visipaque, GE Healthcare); 320 mg/ml]. The 95 
following parameters were used: pitch 1.2 /s, rotation speed 0.5 s, slice thickness 5 mm, 96 
slice gap 1 mm and collimation 0.6 mm. The reference tube voltage was set at 120 kV 97 
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and the reference current was 200 mAs for the abdomen and 110 mAs for the thorax using 98 
automated Care Dose software. 99 
 100 
WB-DWI/MRI scanning 101 
Three Tesla WB-DWI/MRI (Ingenia, Philips Healthcare, Best, The Netherlands) was 102 
performed with parallel radiofrequency transmission and phased-array surface coils. 103 
Free-breathing WB-DWI/MRI was acquired in four imaging stations in the transverse 104 
plane at b=0 and b=1000 s/mm2, covering head to pelvis using the following parameters: 105 
short-T1-inversion-recovery (STIR) prepulse for fat suppression with inversion time (TI) 106 
of 250 ms, b-values in three orthogonal directions of 0 and 1000 s/mm² with automated 107 
calculation of apparent diffusion coefficient  maps, parallel imaging factor of 2.5, 108 
repetition time (TR) of 8454 ms, echo time (TE) of 67 ms, slice thickness of 5 mm, 109 
intersection gap of 0.1 mm, field of view (FOV) of 420 x 329 mm, acquired voxel size of 110 
4.57 x 4.71 mm with a reconstructed voxel size of 2.19 x 2.16 mm. The number of signal 111 
averages (NSA) was 2 for the thorax (with 2 averages for b=0 and 6 for b=1000 s/mm²) 112 
and 1 (with 1 average for b=0 and 3 for b=1000 s/mm²) for all other stations. The number 113 
of slices was 45 for the head and neck imaging station and 50 for the other imaging 114 
stations. Multiplanar reformatted axial, coronal and sagittal WB-DWI/MRI images were 115 
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reconstructed from the transverse b1000 images and combined into a single stack of WB-116 
DWI/MRI images with a slice thickness of 5 mm.  117 
Coronal free breathing single shot Turbo spin-echo (SS-TSE) T2-weighted and breath-118 
hold abdominal-pelvic and thoracic gadolinium-enhanced (Dotarem®, Guerbet, Roissy, 119 
France) 3D T1-weighted gradient-echo sequences were used as anatomical reference. 120 
Coronal SS-TSE T2-weighted images were acquired in 3 imaging stations with parallel 121 
imaging factor of 2, TR/TE of 3000/87 ms, slice thickness of 6 mm, interslice gap op 122 
0.6 mm, FOV of 375 x 447 mm, parallel imaging factor of 4 and 35 slices for all stations. 123 
3D T1-weighted gradient-echo sequences of the pelvis and abdomen were acquired with 124 
parallel imaging factor of 2, TR/TE of 3.6/1.25-2.20 ms, slice thickness of 1.5 mm, 90 125 
slices, FOV 375 x 304 mm, acquired voxel size of 1.49 x 1.50 mm and reconstructed 126 
voxel size of 0.71 x 0.71 mm with 1 NSA. Coronal abdominal mDIXON was acquired 127 
with identical imaging parameters except for a FOV of 400 and 352 slices. Finally, a 128 
twenty seconds breath-hold eTHRIVE of the chest was acquired with identical 129 
parameters as the mDIXON sequences except for a TR/TE of 3.2/1.5 ms, 148 slices and 130 
reconstructed voxel size of 0.98 x 0.97. 131 
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Patients drank one litre of pineapple juice two hours before the WB-DWI/MRI and were 132 
administered an antispasmodic (butylhyoscine, 20 mg IV) to improve the assessment of 133 
the small bowel serosa. Total scanning time was 38 minutes. 134 
 135 
CT image interpretation  136 
An abdominal radiologist with 12 years of experience interpreted the CT. Peritoneal 137 
metastases were recorded when there was nodular, infiltrative or confluent thickening 138 
and/or contrast-enhancement over the peritoneal surfaces, omentum or mesentery. 139 
Involvement of the bowel serosa was recorded in case of bowel masses, thickening or 140 
contrast-enhancement of the bowel wall. 141 
Nodal metastases were characterized based on morphological features indicating necrosis 142 
and short-axis diameter (1 cm threshold for abdominal lymphadenopathies and 0.5 cm 143 
threshold for thoracic lymphadenopathies).13 Pathologically enhancing masses in the 144 
liver, lung, or pleura were recorded as distant metastases.14 145 
 146 
WB-DWI/MRI image interpretation  147 
An abdominal radiologist with 10 years of experience interpreted the WB-DWI/MRI 148 
combining the information of b1000 DW images and anatomical sequences. Peritoneal 149 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
PR
OO
FS
BJ
R 
UN
CO
RR
EC
TE
D 
11 
 
metastases were recorded when there was nodular, infiltrative or confluent b1000 150 
hyperintensity and/or contrast enhancement over the peritoneal surfaces, omentum or 151 
mesentery. Involvement of the bowel serosa was recorded in case of b1000 and/or 152 
contrast-enhancing bowel masses, nodular or infiltrative thickening of the bowel wall. 153 
Lymph nodes were qualitatively assessed based on shape and b1000 signal intensity; 154 
lymph nodes showing (heterogeneous) higher b1000 signal intensity compared to 155 
surrounding lymph nodes were considered malignant.9 Distant metastases were identified 156 
based on increased b1000 signal not attributable to physiologically impeded diffusion or 157 
T2 shine-through.15 158 
 159 
Reference standard 160 
Exploration during laparotomy or laparoscopy with pathology was the primary reference 161 
standard. In case of suspected distant or retroperitoneal nodal metastases critical towards 162 
salvage surgery, image-guided biopsy or fine needle aspiration cytology was performed. 163 
If surgical or histopathological correlation was impossible, correlative FDG-PET/CT 164 
and/or imaging follow-up with consecutive CT or MRI scans for at least 6 months was 165 
used as reference standard. All imaging, surgical and pathological reports used identical 166 
disease site labelling to facilitate proper correlation. The following imaging criteria were 167 
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applied as reference standard in absence of surgical or histopathological correlation: 168 
assessed lesions with FDG uptake not attributable to physiological or inflammatory 169 
uptake at correlative FDG-PET/CT, appearing significantly larger (≥20% increase) 170 
during follow-up or showing a significant decrease (≥30%) under chemotherapy were 171 
considered true positive. Lesions detected at imaging but negative at correlative FDG-172 
PET/CT or resolving without therapy were considered false positive. Sites described 173 
negative at imaging, showing negative correlative FDG-PET/CT or follow-up were 174 
considered true negative. Lesions undetected at imaging, but positive at correlative FDG-175 
PET/CT or showing significant increase (≥20%) during follow-up were considered false 176 
negative. 177 
 178 
Data analysis  179 
STATISTICA 9.1 software (Statsoft Inc, Tulsa, OK, USA) was used with P values below 180 
0.05 indicating statistical significance. CT and WB-DWI/MRI were compared for 181 
detection of tumour recurrence per patient; for assessment of tumour extent in sites critical 182 
towards surgery including according to institutional surgical criteria as mentioned above 183 
and for assessment of operability with the aim for resection to no residual tumour.12 184 
Descriptive statistical data for WB-DWI/MRI and CT (sensitivity and specificity with 185 
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95% binomial confidence intervals (CI), Clopper-Pearson) were determined per patient 186 
and for surgically critical sites. Per-patient statistical differences between WB-DWI/MRI 187 
and CT for detection of recurrence and operability assessment were examined with two-188 
tailed McNemar tests. 189 
 190 
RESULTS 191 
Patients 192 
Fifty-six women were included. After excluding 5 patients without surgical correlation 193 
or follow-up, 51 were analysed (median age 63, range 33-84 years). For all patients, Initial 194 
FIGO stage, histology, primary treatment, diagnosis-to-recurrence interval as well as CA-195 
125 and presence of ascites at time of suspected recurrence are summarized in Table 1.  196 
Figure 1 summarizes the clinical and therapeutic management of patients and use of 197 
standard reference. Ovarian cancer recurrence was confirmed in 48/51 (94%). In 3 198 
patients tumour recurrence was excluded (explorative laparotomy and tumour-free 199 
imaging follow-up during 1 year in 2 patients and tumour-free imaging follow-up during 200 
1 year in 1 patient) (Figure 2). 201 
In 13 patients no attempt for surgery was performed: one patient presented with negative 202 
imaging findings, even on correlative FDG-PET/CT but became progressive under 203 
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imaging follow-up; two patients refused surgery, 5 patients were randomised in the 204 
DESKTOP III chemotherapy arm and 5 patients had poor performance status (Figure 2). 205 
Imaging follow-up was used for correlation of initial findings on WB-DWI/MRI and CT. 206 
Thirty-five patients were considered eligible for surgery, based on clinical criteria alone. 207 
Seventeen of these 35 (49%) of patients underwent salvage debulking surgery with 15 208 
reaching resection to no residual tumour and two being inoperable at laparotomy. 209 
Eighteen of these 35 patients (51%) were deferred from surgery based on imaging 210 
assessment of disease load (Figure 2). The discordant cases between CT and WB-211 
DWI/MRI (9/18, 50%), were assessed with laparoscopy for correlation of peritoneal 212 
disease in three patients, (endoscopic) ultrasound guided biopsy or fine needle aspiration 213 
cytology in 4 patients (one suprarenal, one left supraclavicular, one mediastinal 214 
lymphadenopathy and one pleural metastasis) and FDG-PET/CT in two patients (one 215 
suprarenal and one mediastinal lymphadenopathy). 216 
 217 
Detection of ovarian cancer recurrence 218 
WB-DWI/MRI correctly identified 47/48 (98%) patients with confirmed tumour 219 
recurrence with 94% accuracy compared with 40/48 (83%) for CT showing 78% accuracy 220 
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(p=0.008) (Table 2). In the three patients negative for tumour recurrence, WB-DWI/MRI 221 
was false positive in 2 and CT in all 3 patients. 222 
 223 
Disease extent critical for surgery: WB-DWI/MRI versus CT 224 
Table 2 shows comparative sensitivity and specificity with 95% CI of WB-DWI/MRI and 225 
CT for assessing disease extent critical for surgery following the institutional operability 226 
criteria.12 WB-DWI/MRI showed higher sensitivity for detecting confluent or multifocal 227 
carcinomatosis of the mesenteric root, the small bowel and colon compared with CT 228 
(Figure 3). In addition, WB-DWI/MRI had higher sensitivity for detecting irresectable 229 
metastases compared to CT (Figure 4). 230 
 231 
Prediction of -complete resection: WB-DWI/MRI versus CT 232 
In the 35 patients clinically eligible for salvage surgery, WB-DWI/MRI correctly 233 
predicted operability in 33 of 35 (94%) of patients versus 17 of 35 (49%) for CT 234 
(p<0.001). 235 
In 18 of 35 (51%) patients, WB-DWI/MRI predicted inability of complete resection. 236 
Findings of diffuse peritoneal disease and/or distant metastases were concordant with CT 237 
findings in 9 of 18 (50%) patients and confirmed during further follow-up under systemic 238 
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treatment. In the other 9 of 18 (50%) patients WB-DWI/MRI predicted inoperability in 239 
patients regarded as operable by CT findings (Figure 2). The inoperability was confirmed 240 
either by laparoscopy, image guided biopsy or correlation with FDG-PET/CT in all 9 241 
patients. Compared to CT, WB-DWI/MRI correctly detected diffuse intestinal serosal 242 
spread in three patients, suprarenal or supradiaphragmatic subcentimetric 243 
lymphadenopathies in 5 patients and pleural metastases in one patient. 244 
In 17 of 35 (49%) patients, WB-DWI/MRI predicted complete resection. Complete 245 
resection was possible in 15 of 17 (88%) patients while disease extent was underestimated 246 
in two (12%) patients found inoperable at start of salvage debulking surgery. In 247 
comparison, CT only predicted complete resection in 8 of 17 (47%), underestimated 248 
disease extent in the two (12%) patients found inoperable at start of salvage debulking 249 
surgery and wrongly assigned 7 patients as unable to reach resection to no residual tumour 250 
(Figure 2).  251 
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DISCUSSION 254 
 255 
In this prospective study, WB-DWI/MRI showed higher accuracy than CT for detection 256 
of recurrent ovarian cancer and enabled better prediction of operability with the aim for 257 
complete resection. The better prediction of operability by WB-DWI/MRI over CT was 258 
mainly attributable to the higher sensitivity for detection of multifocal or diffuse serosal 259 
intestinal disease spread, metastases around the central mesenteric vessels and 260 
irresectable distant metastases.  261 
The diagnostic accuracy of 94% for identifying patients with recurrent ovarian cancer by 262 
WB-DWI/MRI in our study is similar with results of a recent publication where whole 263 
body MRI with DWI sequence detected recurrence of gynaecological tumour in 23 of 25 264 
(92%) included patients.16 Previous studies investigating the feasibility of MRI for 265 
detection of ovarian cancer recurrence have yielded variable results with sensitivity 266 
ranging between 57 to 90% and specificity between 33 and 100%.17 Using abdominal 267 
Gadolinium-enhanced MRI alone, Low RN et al found 90% sensitivity, 88% specificity 268 
and 89% accuracy for detecting recurrent or persistent ovarian cancer after cytoreductive 269 
surgery, even in patients with normal CA-125.18 Balestreri et al found 84% sensitivity 270 
and 100% specificity using combined T2-weighted and Gadolinium-enhanced MRI for 271 
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detecting recurrent ovarian cancer in patients with rising tumour marker and negative 272 
thoraco-abdominal CT.19 However, contrary to our study, older reports and a meta-273 
analysis found no significant differences when comparing MRI and CT for detecting 274 
recurrent ovarian cancer.17, 20, 21 Besides lower sample sizes, a number of included studies 275 
in the meta-analysis were performed with different MRI techniques that lacked breath-276 
hold imaging, fat saturation for contrast-enhanced imaging and DWI-sequences. 277 
Substantial advances in MRI technology enabling fast breath-hold fat-saturated 278 
Gadolinium-enhanced imaging and particularly the addition of a (whole body) DWI-279 
sequence are factors that have substantially improved sensitivity for detection of 280 
peritoneal and lymph node metastases.17, 20-22 This probably explains the improved 281 
detection of tumour recurrence and higher accuracy of WB-DWI/MRI over CT in our 282 
study. 283 
More than its ability for detecting tumour recurrence, WB-DWI/MRI outscored CT for 284 
prediction of complete resection. The better prediction of operability by WB-DWI/MRI 285 
over CT in our study is in line with a report in primary ovarian cancer where abdominal 286 
DWI/MRI allowed prediction of suboptimal surgery with 90% accuracy.11 In our study, 287 
WB-DWI/MRI correctly predicted operability in 94% of patients clinically eligible for 288 
salvage surgery. The substantially better detection of disease sites critical for surgery - 289 
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predominantly multifocal or diffuse serosal intestinal metastases, metastases around the 290 
central mesenteric vessels and irresectable distant metastases - was the main contributor 291 
to the better performance for operability assessment by WB-DWI/MRI over CT in our 292 
study. By large, this is explained by the superior contrast resolution of DWI for depiction 293 
of peritoneal and nodal/distant metastases over CT, particularly in the absence of ascites, 294 
in the bowel mesentery and serosa or in subcentimetric lymph nodes.9, 22, 23  295 
Previously, doubt was cast on the diagnostic capacity of stand-alone WB-DWI/MRI for 296 
detection of recurrent gynaecological tumour, presumably by the impeding effects of 297 
post-therapeutic fibrosis and tissue scarring.16 However, radiological-pathological 298 
correlation in treated head and neck cancer has shown that the low cellular density and 299 
large interstitial space of fibrosis corresponded with low signal intensity on high b-value 300 
DWI-images, while the hypercellularity and restricted interstitial space in tumour 301 
recurrence resulted in increased signal intensity in on high b-value DWI-images. As such, 302 
DWI allows to differentiate recurrent tumour from treatment induced fibrosis or 303 
inflammation irrespective of anatomical or metabolical imaging findings.24  304 
The ability for precise diagnosis of recurrent cancer by DWI was confirmed in two 305 
studies, evaluating DWI for assessment of recurrent pelvic cancer. Lambregts et al found 306 
that the addition of DWI to the conventional MRI protocol reduced the number of false 307 
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positives by 20% and improved interobserver agreement, thereby improving radiologist 308 
confidence.25 In that study, all 8 patients with equivocal CT findings in this study were 309 
correctly diagnosed by DWI/MRI suggesting superior sensitivity and specificity for 310 
DWI/MRI over CT. Kitajima et al showed that DWI had significantly better sensitivity 311 
and accuracy relative to T2-weighted MRI with equal performance as contrast-enhanced 312 
MRI in 62 patients with suspected intrapelvic recurrence of gynaecological cancers.26 313 
Importantly, adding DWI allowed better detection of metastatic disease sites other than 314 
the suspected site of tumour recurrence allowing better description of total disease extent 315 
which may be useful for surgical planning.  316 
Accordingly, in our study, the better description of total disease extent and improved 317 
sensitivity for small tumoral deposits enabled WB-DWI/MRI to better identify patients 318 
with peritoneal disease spread, lymphadenopathies or distant metastases beyond surgical 319 
reach compared to CT and thus better identify patients who would not benefit from 320 
salvage surgery due to incomplete resection. Contrary, the better differentiation of tumour 321 
recurrence from post-treatment tissue distortions, particularly mesenteric infiltration not 322 
attributable to tumour, enlarged reactive lymph nodes and liver lesions allowed WB-323 
DWI/MRI to better predict complete resection compared to CT, the latter wrongly 324 
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assigning 7 patients as having peritoneal or distant lymphadenopathies/metastases beyond 325 
surgical reach. 326 
While optimal salvage debulking surgery may improve median survival, its success 327 
depends on early detection of recurrence and thorough patient selection.27 In order to 328 
optimize patient selection, clinical predictive score models including the AGO score and 329 
the model of Tian have been validated to overcome current radiological limitations for 330 
predicting complete resection.28 In the DESKTOP II study - validating the AGO-score - 331 
half of the patients had far more peroperative tumour load than predicted by imaging and 332 
in one quarter of the patients disease load was overestimated by imaging, while the AGO-333 
score correctly predicted complete resection in 76% of patients.5, 29 However, as a 334 
drawback, the AGO-score is currently not designed to predict inoperability in negatively-335 
scored patients.5, 29 Also, while both models have high positive predictive value for 336 
complete resection of 82% and 80. 3% respectively, they suffer from relatively high false 337 
negative rates 68.5% and 55.6% respectively.28 It is currently unclear whether diagnostic 338 
laparoscopy could enhance the predictive value of both models, bearing in mind an 339 
associated morbidity rate of 1-5%.28, 30, 31 The high accuracy of WB-DWI/MRI of 94% 340 
for predicting operability and ability to identify both patients with under- and 341 
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overestimated disease load by CT suggests its potentially additional value to clinical 342 
predictive models for operability assessment in patients with recurrent ovarian cancer. 343 
This study has some limitations. Firstly, direct surgical or pathological correlation was 344 
not available for all disease sites. However, laparoscopy or -tomy in patients in whom 345 
surgery was not indicated was considered non-ethical and meticulous imaging follow-up 346 
was used instead. As per study design, lesions considered critical for surgical planning 347 
were confirmed by biopsy or laparoscopy.  348 
Secondly, the patient population with direct surgical correlation was relatively small. 349 
However, this is inherent to the design of a single-centre pilot study for which only a 350 
selected number of patients are eligible for salvage surgery. Therefore the results of this 351 
study need to be validated in larger study populations. 352 
Thirdly, we did not compare the results of WB-DWI/MRI with FDG-PET/CT. Not all 353 
patients with suspected recurrent ovarian cancer receive routine clinical FDG-PET/CT in 354 
our centre due to its reported relatively low performance to predict complete resection.5 355 
Nevertheless, future comparative studies are warranted to elucidate the potential 356 
synergistic value of microstructural and metabolic imaging, especially in the advent of 357 
the development of hybrid PET/MRI.16 358 
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Last, we did not assess interobserver agreement. However, a recent study showed good 359 
interobserver agreement using similar interpretation criteria.9 360 
 361 
In conclusion, WB-DWI/MRI showed high accuracy, superior to CT, for detection of 362 
ovarian cancer recurrence and prediction of complete resection in patients with clinical 363 
symptoms or increase of tumour marker. WB-DWI/MRI particularly improved the non-364 
invasive assessment of multifocal or diffuse serosal intestinal tumour spread, metastatic 365 
deposits around the central mesenteric vessels and irresectable distant metastases. 366 
Our study suggests that WB-DWI/MRI could substantially improve clinical management 367 
and patient selection for salvage surgery pending validation in larger studies. 368 
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TABLES 472 
Table 1 Patient demographics 473 
 n (%) 
Median age (y)                                           63 (range, 33-84)  
  
Initial FIGO* stage 
  Borderline 
  I 
  II 
  III 
  IV 
  Unknown 
 
1 (2) 
3 (6) 
4 (8) 
31 (61) 
7 (14) 
5 (10) 
  
Histology 
  Serous papillary adenocarcinoma 
  Adult granulosa cell tumour 
  Clear cell carcinoma 
  Serous cystadenocarcinoma 
  Endometrioid carcinoma 
  Sertoli-Leydig cell tumour 
  Borderline mucinous tumour 
  Dysgerminoma (immature teratoma) 
  Carcinosarcoma  
  Unknown  
 
36 (71) 
5 (10) 
2 (4) 
2 (4) 
1 (2) 
1 (2) 
1 (2) 
1 (2) 
1 (2) 
1 (2) 
  
Primary treatment 
  Primary debulking surgery  
    R0 resections** 
 
38 (75) 
  38 (100) 
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  Interval debulking surgery after neoadjuvant chemotherapy 
    R0 resections 
    Rest < 1cm 
13 (25) 
  12 (92) 
  1 (8) 
  
Diagnosis-to-recurrence interval (months) 
  Median (min-max)                                   31 (range, 5-285) 
 
 
  
Pre-operative CA-125*** 
  > 35 U/mL  
  < 35 U/mL 
  unknown 
 
Ascites 
  No ascites 
  Limited ascites  
  Moderate ascites 
  Severe ascites 
 
29 (57) 
19 (37) 
3 (6) 
 
 
43 (84) 
5 (10) 
1 (2) 
2 (4) 
*FIGO, International Federation of Gynaecology and Obstetrics;  
**R0 resection, complete resection;  
***CA-125, Cancer Antigen-125 
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Table 2 Comparative sensitivity and specificity for detection of recurrent disease and disease 
extent according to operability criteria between CT and WB-DWI/MRI 
  
Sensa (%) 
TP/(TP+FN) 
95% CIc 
Specb (%) 
TN/(TN+FP) 
95% CI 
LLd  
(%) 
ULe 
(%) 
LL  
(%) 
UL  
(%) 
Detection of recurrent disease 
Detection of recurrence WB-DWI/MRI 98 (47/48) 89 100 33 (1/3) 1 91 
 CT 83 (40/48) 70 93 0 (0/3) 0 71 
Peritoneal carcinomatosis 
Superior mesenteric artery involvement WB-DWI/MRI 100 (2/2) 20 100 100 (49/49) 91 100 
  CT 50 (1/2) 3 97 100 (49/49) 91 100 
Diffuse infiltration of mesenteric root of small bowel WB-DWI/MRI 92 (12/13) 62 100 97 (37/38) 85 100 
  CT 31 (4/13) 10 61 100 (38/38) 89 100 
Diffuse and confluent carcinomatosis of stomach WB-DWI/MRI 100 (6/6) 52 100 100 (45/45) 90 100 
  CT 50 (3/6) 14 86 96 (43/45) 84 99 
Diffuse and confluent carcinomatosis of small bowel WB-DWI/MRI 93 (13/14) 64 100 95 (35/37) 80 99 
  CT 21 (3/14) 6 51 95 (35/37) 80 99 
Intrahepatic M+ WB-DWI/MRI 100 (1/1) 5 100 100 (50/50) 91 100 
  CT 0 (0/1) 0 95 92 (46/50) 80 97 
Infiltration of large vessels of lig.f hepatoduodenale WB-DWI/MRI 100 (6/6) 52 100 100 (45/45) 90 100 
  CT 33 (2/6) 6 76 100 (45/45) 90 100 
Metastases behind the porta hepatis WB-DWI/MRI 100 (7/7) 56 100 98 (43/44) 86 100 
  CT 29 (2/7) 5 70 98 (43/44) 86 100 
Multifocal or confluent carcinomatosis of colon WB-DWI/MRI 91 (10/11) 57 100 98 (39/40) 85 100 
  CT 27 (3/11) 7 61 100 (40/40) 89 100 
Distant metastases 
Resectable inguinal lymph nodes WB-DWI/MRI 100 (1/1) 5 100 98 (49/50) 88 100 
  CT 100 (1/1) 5 100 96 (48/50) 85 99 
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Solitary resectable retrocrual or paracardial nodes WB-DWI/MRI 100 (1/1) 5 100 100 (50/50) 91 100 
  CT 100 (1/1) 5 100 98 (49/50) 88 100 
Irresectable distant metastases  WB-DWI/MRI 90 (9/10) 54 99 100 (41/41) 89 100 
  CT 20 (2/10) 4 56 98 (40/41) 86 100 
aSens, sensitivity;  
bSpec, specificity;  
c95% CI, 95% binomial confidence interval (Clopper-Pearson);  
dLL, lower limit;  
eUL, upper limit;  
flig., ligamentum;  
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Figure 1: Flowchart describing the process of clinical decision making towards salvage surgery 
following the imaging results; any case of conflicting imaging results that would potentially 
defer eligible patients from possible salvage surgery was correlated by either surgical 
exploration, biopsy of the surgically-critical suspect lesion or correlative imaging. 
 
Figure 2: Clinical and therapeutic management of patients and use of standard reference. 
 
Figure 3: Sixty-eight-year-old woman with previously treated stage IV serous papillary ovarian 
cancer shows increased serum CA-125. WB-DWI/MRI shows carcinomatosis of the stomach, 
small bowel and colon and peritoneal metastases  depicted as diffuse linear or nodular b1000 
hyperintensity of the serosal surfaces (arrows) (A, B, E, F) in correlation to T2-weighted 
imaging (C). CT was interpreted as negative (D, G, H). Lesion progression at imaging follow-
up during six months confirmed peritoneal carcinomatosis. 
 
Figure 4: Seventy-one-year-old woman with previous history of high grade serous papillary 
ovarian carcinoma with increased serum CA-125. Whole body DWI/MRI shows b1000 
strongly hyperintense mediastinal lymph nodes suspect for lymphadenopathies (dashed arrows) 
(A, B, C), interpreted as negative at CT (D, E, F). Cytology after endoscopic fine-needle 
aspiration confirmed these nodal metastases. 
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